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Whitewater Arroyo virus (WWAV) is a North American New World arenavirus, first isolated from rats in New Mexico in 1993, and tentatively
associated with three human fatalities in California in 1999–2000. However, it remains unclear whether WWAV was the cause of these, or any
other, human infections. One important characteristic of viruses that influences pathogenic potential is the choice of cellular receptor and the
corresponding tropism of the virus. In the arenaviruses, these properties are determined largely by the viral glycoprotein (GP). We have previously
noted for the New World clade B arenaviruses, which include four severe human pathogens, that the ability to cause human disease correlates with
the ability of the GP to use the human transferrin receptor 1 (hTfR1) to enter cells. In addition, pseudotyped retroviral vectors displaying the GPs
from pathogenic clade B viruses transduced a range of cell lines in vitro that were distinct from those that could be transduced by non-pathogenic
clade B viruses. WWAV was initially classified as a New World clade A virus, based on sequence analysis of its nucleoprotein gene. However,
more extensive analyses have revealed that WWAV and the other North American arenaviruses are probably recombinant clade A/B viruses, and
that the WWAV GP is more closely related to the clade B GPs. Based on this finding, we sought to understand more about the possible pathogenic
potential of WWAV by determining whether its clade B-like GP exhibited the characteristics of a pathogenic or non-pathogenic clade B virus. Our
studies found that WWAV GP did not use hTfR1 for entry, and that its overall in vitro tropism was most similar to the GPs from the non-
pathogenic clade B viruses. Although many viral factors in addition to GP receptor use and tropism determine whether a virus is able to cause
disease in humans, our analysis of the WWAV GP does not support the idea that WWAV is a human pathogen.
© 2007 Elsevier Inc. All rights reserved.Keywords: Arenavirus; Whitewater Arroyo virus; Cellular receptor; Viral tropism; Viral pathogenicity; Emerging virusIntroduction
The arenaviruses are enveloped, single-stranded RNAviruses,
of interest because five members of the group can cause severe
hemorrhagic fevers in humans, with mortality rates reaching 20%
(Geisbert and Jahrling, 2004). The family is divided into two
groups, Old World and New World viruses, based initially on
serologic cross-reactivity and geographic distribution, and later
confirmed by genomic sequence analyses (Clegg, 1993; Bowen
et al., 1996). The vast majority of the arenaviruses are vectored by⁎ Corresponding author. Department of Research Immunology and Bone
Marrow Transplantation, Childrens Hospital Los Angeles, 4650 Sunset
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doi:10.1016/j.virol.2007.10.004rodents, in which they cause persistent infections, with the
possible exception of Tacaribe virus (TCRV), which was isolated
from bats (Downs et al., 1963). The distribution of the viruses is
restricted to the areas that are populated by their specific rodent
vector, and humans are accidental hosts, being occasionally
infected by contact with rodent excreta.
The human pathogens in the Old World arenaviruses comprise
Lassa fever virus (LASV) and lymphocytic choriomeningitis virus
(LCMV). Lassa fever is a febrile illness, restricted to Western
Africa, that in severe cases can lead to pulmonary edema, res-
piratory distress, bleeding from mucosal surfaces, and shock
(McCormick et al., 1987). In contrast, LCMVis more widespread,
being vectored by the common housemouseMusmusculus, and is
the only Old World arenavirus found in North America. LCMV
infection can be asymptomatic or cause febrile CNS disease
Fig. 1. Recombinant origin for the North American New World arenaviruses.
Sequence comparison of the GP and NP genes from the NewWorld arenaviruses
revealed three distinct clade, A, B, and C. In addition, the North American
arenaviruses, that include WWAV, are most closely related to clade A in the NP
gene, but clade B in GP. A/B Rec. refers to this putative recombinant lineage. The
strains that are pathogenic for humans (⁎) are found throughout clade B, in each
of the three distinct sub-groups, B1, B2 and B3. The pathogenicity of WWAV
remains unclear. Adapted from Charrel et al., 2001, 2002).
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(Jamieson et al., 2006; Sheinbergas, 1976). It was recently asso-
ciated with fatal outcomes in immunosupressed patients receiving
organ transplants (Fischer et al., 2006).
The New World complex comprises 18 members, distributed
between three clades, A, B, and C (Bowen et al., 1996; Charrel
and de Lamballerie, 2003) (Fig. 1). Clade B contains four known
human pathogens, capable of causing hemorrhagic fevers in
South America; Junin (JUNV), Machupo (MACV), Guanarito
(GTOV), and Sabia (SABV) viruses, that cause Argentine,
Bolivian, Venezuelan, and Brazilian hemorrhagic fevers, respec-
tively. Clade B also contains three non-pathogenic members.
North America is home to three New World arenaviruses,
carried by members of the Cricetidae rodent family. Tamiami
virus (TAMV) was isolated from hispid cotton rats (Sigmodon
hispidus) in Florida in 1963 (Calisher et al., 1970; Jennings et al.,
1970). Whitewater Arroyo virus (WWAV) was isolated from
white-throated woodrats (Neotoma albigula) in 1993 (Fulhorst
et al., 1996) and has subsequently been found in other Neotoma
and Peromyscus species, including deer mice (P. maniculatus).
Most recently, Bear Canyon virus (BCNV) was isolated from
California mice (P. californicus) in California in 2002 (Fulhorst
et al., 2002), and is also carried by large-eared woodrats
(N. macrotis) (Cajimat et al., in press).
There has been considerable interest in WWAV since 2000,
when a preliminary report implicated it in the deaths of three
people in California (CDC, 2000; Enserink, 2000). The patients
presented with febrile illness and respiratory distress, with twodeveloping hemorrhagic symptoms and liver failure. However,
only one of the victims reported a possible contact with rodent
droppings before becoming ill, and no subsequent reports have
appeared confirming these initial findings. Therefore, the asso-
ciation of WWAV with these or any other human infections
remains to be established.
The arenavirus genome consists of two RNA strands, a large
(L) strand of about 7200 nucleotides and a small (S) strand of
about 3500 nucleotides. Each codes for two proteins, arranged
in non-overlapping open reading frames of opposite (ambi-
sense) orientation. The S segment codes for the glycoprotein
(GP) and nucleoprotein (NP), whereas the L segment carries the
viral polymerase (L) and a zinc-finger-like protein (Z).
The phylogeny of the arenaviruses have been traditionally
based on a 613–649 nucleotide sequence of the NP gene (Bowen
et al., 1997). Based on such analyses, WWAV was initially
classified as a clade A virus. Subsequently, a more extensive
analysis of a 3178 nucleotide sequence of the S strand revealed
that the GP gene had closer homology to the GP of clade B
viruses (Archer and Rico-Hesse, 2002; Charrel et al., 2001).
Similar findings were obtained upon analysis of the S strands
from TAMV and BCNV, but not in any South American
arenaviruses (Charrel et al., 2002), leading to the suggestion that
the three North American arenaviruses represent a phylogenetic
lineage that originated by recombination between clade A and B
viruses, and are separate from the other South American viruses
(Fig. 1).
Receptor use by viruses has a significant influence on viral
tropism and pathogenicity. The arenaviruses are known to infect
a wide range of cell types across many different species
(Reignier et al., 2006; Rojek et al., 2006), suggesting that they
may be able to use different cellular receptors. To date, two
distinct arenavirus receptors have been identified; α-dystrogly-
can (α-DG), which is used by LASV, certain isolates of LCMV,
and the New World clade C viruses Oliveros and Latino (Cao
et al., 1998; Kunz et al., 2004, 2005; Reignier et al., 2006;
Spiropoulou et al., 2002), and human transferrin receptor 1
(hTfR1), which is used by certain clade B viruses for entry into
human cells (Radoshitzky et al., 2007; Flanagan et al., 2007).
Using GP pseudotyped retroviral vectors as surrogates for
arenavirus entry, we have recently demonstrated that hTfr1 is not
the only receptor to be used by clade B viruses. Although the
pathogenic members of the clade B lineage can use hTfR1 to
enter cell lines in vitro, the non-pathogenic members TCRVand
Amapari (AMAV) use entry pathways that are independent of
either α-DG or hTfR1 (Flanagan et al., 2007). We have also
observed marked differences in the ability of clade B GPs to
direct entry into human and rodent lymphocyte cell lines, and
which also segregate between the pathogenic and non-
pathogenic clade B viruses (Oldenburg et al., 2007), and tropism
differences between GTOV and AMAV have also previously
been noted (Rojeck et al., 2006). Taken together, these studies
demonstrate that receptor use and tropism characteristics of the
GP can distinguish human pathogens from non-pathogens in the
clade B lineage. Since sequence comparisons have revealed that
theWWAVGP is closely related to the clade BGPs, and because
the ability of this virus to cause human disease is unclear, we
Fig. 2. Titers of GP pseudotyped retroviral vectors on various cell lines. Titers
were measured on (A) human kidney endothelial cells (293A), human T
lymphocytes (CEM), and murine T lymphocytes (TIB27), and (B) rodent cell
lines. Values shown are mean±SE for 2–8 independent experiments. All vector/
cell combinations that gave no titer (⁎) were confirmed using 10× concentrated
stocks of vectors.
Fig. 3. NH4Cl sensitivity. Effect of NH4Cl treatment on titer of indicated vectors
on (A) 293A and (B) K562 cells. In each case, the titers were made relative to the
values obtained in the absence of drug. Control vectors were pseudotyped with
the amphotropic murine leukemia virus (A-MLV) Env, which is pH-independent
and VSV-G, which is pH-dependent.
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GP exhibited the same characteristics as the GPs from the clade
B human pathogens.
Results
Generation of WWAV GP pseudotyped retroviral vectors
Retroviral vectors pseudotyped with arenaviruses GPs have
proved to be useful tools with which to study arenavirus entry as
they exhibit entry characteristics and tropism patterns similar to
the parental arenaviruses (Oldenburg et al., 2007; Reignier
et al., 2006, Rojek et al., 2006). We generated retroviral vectors
carrying the GP from the prototype WWAV strain AV 9310135,
originally isolated from the kidney of an infected white-throated
woodrat (Fulhorst et al., 1996). Since the vectors encode a GFP
reporter gene, the ability of the WWAV GP to direct entry into
cells could be assessed by measuring GFP expression in a target
population by FACS analysis at 48 h post-transduction.
The titer of the WWAV vectors was initially measured on
human 293A cells and compared to the titers obtained with a
panel of GP pseudotyped vectors, including LASV, MACV, and
TCRV. As a control, we used vectors pseudotyped with the
vesicular stomatitis virus glycoprotein (VSV-G), which confers a
very broad tropism to retroviral vectors and is used to control for
the transduction efficiency of retroviral vectors on all the cell lines
tested. Unconcentrated supernatant stocks of the WWAV vectorsproduced a titer of approximately 2.5×104 transducing units per
ml (Fig. 2A), which is a similar to the titers we have previously
observed for other clade B vectors (Oldenburg et al., 2007).
WWAV tropism on human and rodent cell lines
We have previously characterized the in vitro tropism of GPs
from different arenaviruses bymeasuring their ability to transduce
a panel of cell lines. The GPs were derived from the Old World
viruses LASV and LCMV, and the New World clade B viruses
JUNV, MACV, GTOV, TCRV, and AMAV. These initial screens
identified specific cell lines that revealed differences in the tropism
of the different GPs. For example, we found that lymphocyte cell
lines produced three distinct patterns of entry: LASVand LCMV
vectors were unable to efficiently transduce either human or
rodent lymphocytes, pathogenic clade B vectors such as MACV
could transduce human CEM lymphocytes but not mouse TIB27
lymphocytes, while non-pathogenic clade B vectors such as
TCRV could infect TIB27 but not CEM cells (Oldenburg et al.,
2007). In addition, we observed differences in the relative
efficiency with which different clade B vectors could transduce
rodent cell lines (Oldenburg et al., 2007). Together these
observations provided a tropism profile that could distinguish
between the pathogenic and non-pathogenic clade B GPs.
Fig. 5. Effect of hTfR1 on vector titers on CHO-K1 cells. (A) Flow cytometric
analysis of CHO-K1 and TRVb-1 cells was performed using an anti-hTfR1
antibody. TRVb-1 cells do not express endogenous CHO-K1 TfR1 but are stably
transfected with hTfR1. Narrow lines represent secondary antibody only. (B)
Comparison of vector titers on CHO-K1 versus TRVb-1 cells. Values shown are
mean±SE for of 3–8 independent experiments.
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to transduce human CEM T lymphocytes and murine T1B27 T
lymphocytes. We observed that they were unable to transduce
CEM cells, even when concentrated stocks of vectors were
used. In contrast, T1B27 cells were susceptible to the WWAV
vectors (Fig. 2A). Comparison to MACV and TCRV vectors,
which are representative pathogenic and non-pathogenic clade
B viruses, respectively, revealed that the WWAV GP properties
are more similar to the non-pathogenic clade B GP.
Next, we examined the ability of the WWAV vectors to
transduce three different rodent cells lines, NIH 3T3, CHO-K1,
and BHK21 cells, in comparison to VSV-G, LASV, MACV, and
TCRVGPvectors (Fig. 2B). In agreementwith the results from the
lymphocyte studies, we found that the WWAV vectors were more
similar to the TCRV vectors than the MACV vectors. Together,
these data show that the WWAV GP has entry characteristics that
are most similar to the non-pathogenic clade B GPs.
Low pH requirement for WWAV entry
Upon cell entry, some viruses require the acidic environment
of the endosome in order to trigger virus-cell fusion. We have
previously noted that within the clade B1 viruses, this require-
ment is virus- and cell-type specific (Oldenburg et al., 2007).
Specifically, while all clade B1 GPs tested were sensitive to
inhibition by NH4Cl on 293A cells, TCRV entry was markedly
more sensitive than either JUNVor MACVentry when tested on
K562 cells. We therefore examined the pH-sensitivity of
WWAV entry using both 293A and K562 cells (Fig. 3). The
data revealed that the characteristics of WWAV entry are most
similar to TCRV entry, being pH-sensitive on both cell lines.
WWAV GP does not use α-DG
α-DG was the first receptor described for the arenavirus
family, and can be utilized by LASV, certain strains of LCMV,
and clade C viruses (Cao et al., 1998; Kunz et al., 2004, 2005;
Reignier et al., 2006; Spiropoulou et al., 2002). We have also
shown that it is not required for entry by the clade B viruses,Fig. 4. Effect of DG expression in murine ES cells on vector titers. The titers of
GP pseudotyped vectors were measured on DG −/− and +/−murine ES cells and
the ratios determined. Values were normalized to the ratio obtained with VSV-G
vectors, to control for any differences between the two cell lines in their ability to
support retroviral vector transduction. LASV GP vectors were highly dependent
on DG for entry, while MACVand WWAV GP vectors were not affected by the
loss of DG. Values shown are mean±SE for 2–3 independent experiments.since both pathogenic and non-pathogenic GP pseudotyped
vectors transduce equally well murine embryonic stem (mES)
cells with and without DG (Reignier et al., 2006; Oldenburg
et al., 2007). We therefore determined the titers of WWAV
vectors on DG +/− and −/− mES cells. The WWAV vectors
gave equivalent titers on the two cell lines when normalized to
control VSV-G vectors, showing no requirement for α-DG for
entry (Fig. 4).
Human transferrin receptor 1 use by WWAV GP
Human transferrin receptor 1 (hTfR1) was recently identified
as a cellular receptor that can be used by clade B viruses to gain
entry into human cells (Radoshitzky et al., 2007). Our sub-
sequent studies have shown that hTfR1 can only be used by the
pathogenic clade B GPs (JUNV, MACV, and GTOV), but not
by the non-pathogenic GPs from TCRV or AMAV (Flanagan
et al., 2007). Accordingly, the ability to use hTfR1 for entry can
be considered to be a property that distinguishes the pathogenic
and non-pathogenic clade B GPs.
We examined whether WWAV GP entry into cells utilized
hTfR1. First, we compared the titers of the panel of pseudo-
typed vectors on CHO-K1 cells and TRVb-1 cells. TRVb-1 cells
are CHO-K1 derivatives, which do not express functional
endogenous TfR1, but stably express human TfR1 (McGraw
et al., 1987). It has been shown that the presence of hTfR1 in
CHO-K1 cells increases the titers of MACV vectors but not
TCRV (Flanagan et al., 2007).
Fig. 6. Role of hTfR1 in viral entry. Human 293A (A) and rodent TRVb-1 (B) cells were pretreated with anti-hTfR1 antibody at two different doses, then challenged
with the indicated pseudotyped vectors. Titers were converted to percent of control (titers obtained with no antibody pretreatment). Data are reported as mean±SE of 2
independent experiments. (C) Titers of pseudotyped retroviral vectors on mock transfected CHO-K1 cells, or cells transiently transfected with an expression plasmid
for hTfR1. Values shown are mean±SE for 3 independent experiments. (D) Western blotting confirming expression of hTfR1.
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TRVb-1 cells by FACS analysis using an anti-CD71 antibody,
which specifically recognizes the human form of TfR1 (Fig. 5A).
Examination of the titers of the vectors on the two cell lines
confirmed that the MACV vector titers were increased by the
presence of hTfR1 by approximately 2 orders ofmagnitude, while
the VSV, LASV, and TCRV vectors were not significantly
different between the two cell lines (Fig. 5B). This suggests that
WWAV GP does not use hTfR1 as a receptor.
To confirm this result, we performed antibody inhibition
studies by pre-treating human 293A and TRVb-1 cells with an
anti-hTfR1 antibody before adding pseudotyped vectors. We
observed a significant reduction in titer for the MACV vectors
on both cell lines, even at the lowest dose of antibody used
(5 nM). In contrast, the titers of the VSV, TCRV, and WWAV
vectors were only slightly inhibited at the higher dose (50 nM)
(Figs. 6A, B). Finally, we transiently expressed hTfR1 in CHO-
K1 cells and showed that only the titer of theMACV vectors was
increased (Fig. 6C). Together, these data show that the WWAV
GP does not use hTfR1 to enter cells. Combined with the
observations of tropism on the panel of human and rodent cell
lines, we conclude that WWAV GP behaves more like the non-
pathogenic members of clade B than the pathogenic members.
Discussion
The possibility that WWAV is a new, rodent-borne human
pathogen was first suggested in 2000, when a report from the
CDC speculated that the virus had caused three fatalities inCalifornia in 1999–2000. However, no follow-up information
has appeared since that initial report, and there have been no
further cases of human infection. Therefore, the status ofWWAV
as a human pathogen remains unclear.
WWAV is part of a distinct lineage in the New World
arenaviruses that also include BCNV and TAMV. Sequence
analysis indicates a recombinant origin for these North American
viruses, with the S strand of the virus containing clade A-like
sequences in the NP gene, but clade B-like sequences in the GP
gene. A proposed crossover point has been mapped to the 3′ end
of the GP gene (Charrel et al., 2001).
The fact that WWAV has a clade B-like GP is of interest
because the clade B arenaviruses include four highly pathogenic
viruses that cause severe hemorrhagic fevers in South America.
In addition, three clade B viruses have been identified to date
that are not associated with human disease. We have described
marked differences in the properties of the GPs from pathogenic
and non-pathogenic members of clade B that do not align with
the phylogenetic relationships in this clade (B1, B2, and B3
viruses) but, instead, correlate with the ability of the viruses to
infect humans (Flanagan et al., 2007). We speculate that these
differences are likely due to differences in receptor use and
entry pathways and, as such, will represent important deter-
minants of in vivo pathogenicity.
Since WWAV has a clade B-like GP, we hypothesized that its
human pathogenic potential could be revealed by an analysis of
the characteristics of its GP. Using WWAV GP pseudotyped
retroviral vectors, we analyzed several properties, including the
ability to transduce human and rodent cell lines, the requirement
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The results of these analyses suggested that the WWAV GP has
properties that are most similar to the non-pathogenic members
of clade B. In addition, we found that as well as not requiring
hTfR1 to enter cells, WWAV GP also did not use α-DG.
Therefore, similar to the findings for TCRVandAMAV (Flanagan
et al., 2007; Rojek et al., 2006), WWAV seems to use an ad-
ditional, unidentified receptor.
WWAV was originally isolated in 1993 from N. albigula
white-throated woodrats from New Mexico (Fulhorst et al.,
1996) and has now been found in seven Western states (Fulhorst
et al., 1996). However, human infections attributed to a North
American arenavirus have been limited to the 2000 CDC report.
A survey of 1094 sigmodontine and 112 murine rodents trapped
in Southern California between 1995 and 1998 showed that
antibodies to WWAV were found in N. fuscipes, N. lepida,
Reithrodontomys megalotis, as well as four other species of
Peromyscus rodents. In particular, P. maniculatus, the deer
mouse, was found to carry WWAV-specific antibodies (Bennett
et al., 2000). This may be significant for human health since this
rodent is known to invade human habitations. However, only a
very low incidence of seropositivity has been found among
individuals who are in frequent contact with various wild
rodents, with no reported cases of infection or death from are-
naviruses in this vulnerable population (Fulhorst et al., 2007).
Therefore, the likelihood of a widespread outbreak of an North
American arenavirus infection in the general population seems
to be small.
Although our data indicate that it is unlikely that WWAV is a
human pathogen, we caution that an obvious limitation of any
study using GP pseudotyped vector systems is that the patho-
genicity of a virus will depend on factors other than just receptor
use. Receptor binding and viral entry are just one part of the life
cycle of a virus and the complex host–virus interactions that
occur downstream of the entry step remain to be described for a




293T, NIH3T3, CHO-K1, CEM, TIB27, and BHK21 cells
were obtained from the American Type Culture Collection and
293A cells were obtained fromQBiogene (Irvine, CA). The cells
were maintained in D10 medium: Dulbecco's modified Eagle's
medium (DMEM) (Mediatech, Herndon, VA) supplemented
with 10% fetal bovine serum (FBS) (Hyclone, Logan, UT) and
2 mM glutamine (Gemini Bio-Products, West Sacramento, CA)
except CEM cells, which were maintained in R10 medium:
RPMI (Mediatech) supplemented with 10% FBS and 2 mM
glutamine. TRVb-1 cells (McGraw et al., 1987) were a gift from
Dr. Timothy McGraw and were cultured in D10. Dystroglycan
knockout (−/−) and heterozygous control (+/−) R1 murine
embryonic stem cells (Williamson et al., 1997) were generously
provided by Dr. Stefan Kunz (The Scripps Research Institute),
and Dr. Kevin Campbell (University of Iowa), respectively, andcultured in DMEM supplemented with 20% FBS, 2 mM
glutamine, 1 mM non-essential amino acids (Chemicon, Teme-
cula, CA), 0.001% β-mercaptoethanol (Sigma), and 103 U/ml of
murine leukemia inhibiting factor (ESGRO, Chemicon). All cells
were maintained in 5% CO2, except TIB27 cells, which were
maintained in 10% CO2.
Retroviral vector production and titer determination
Retroviral vectors displaying arenavirus GPs were produced
by transient transfection of 293Tcells using plasmid pCgp, which
expresses murine leukemia virus Gag-Pol, plasmid pMND-eGFP
which is a retroviral vector genome expressing the enhanced
green fluorescent protein (eGFP) reporter gene, and the
appropriate GP expression plasmid, essentially as described
(Reignier et al., 2006). The viral GPs that were used were derived
from VSV, MACV (Carvallo strain, accession no. AY129248),
LASV (Josiah strain, accession no. AY628203), and TCRV
(Reignier et al., 2006). The GP fromWWAV (strain AV 9310135,
accession no AF228063) was chemically synthesized as a codon-
optimized version for improved expression in human cell lines
and was cloned into the expression vector pCAGGS (Niwa et al.,
1991). Retroviral vector supernatants were harvested 48 h post-
transfection filtered through a 0.45 μm filter (Millipore Corp.,
Bedford, MA), and aliquots were stored at −80 °C. Concentrated
(10×) vector stocks were generated by ultrafiltration using
Centricon Plus-20 30 kDa MWCO columns (Millipore). The
titer of the vectors on specific target cells was obtained by
incubation of cells with vector stocks, followed by FACS analysis
on a FACScan flow cytometer (Becton Dickinson, Franklin
Lakes, NJ), for eGFP expression 48 h later. Titers were expressed
as transducing units per ml (TU/ml), calculated bymultiplying the
percentage of eGFP positive cells in a sample by the number of
cells present at the time of transduction, and taking into account
any dilution factors.
pH-dependence assay
Five×105 K562 or 293A cells were pre-treated for 1 h with
50 mM NH4Cl (Sigma), then vector supernatant containing
50 mM NH4Cl was added to the cells and incubated for a further
3 h. The cells were then washed with PBS and incubated in 2 ml
fresh D10 media for 48 h, when the vector titers were determined
by FACS analysis as described above. Control transductions were
performed in the absence of NH4Cl, and the percent titer for the
drug treatment arm compared to the control cells was calculated.
Control vectors were included that were pseudotyped with the pH
sensitive glycoprotein from VSV, and the pH-insensitive am-
photropic murine leukemia virus Env protein.
Human TfR1 cell surface expression
Five×105 CHO-K1 or TRVb-1 cells were washed and
incubated in phosphate buffered saline (PBS) containing 1%
bovine serum albumin for 10 min. The cells were kept on ice
throughout the procedure. The cells were incubated with a 1:50
dilution of themouse anti-humanCD71 antibody (cloneM-A712,
445T. Reignier et al. / Virology 371 (2008) 439–446BD Biosciences, San Jose, CA) for 30 min, washed, and incu-
bated with a 1:200 dilution of fluorescein isothiocyanate FITC-
conjugated anti-mouse IgG antibody (Jackson ImmunoResearch,
West Grove, PA) for 25 min. The cells were analyzed on a
FACSCalibur flow cytometer (Becton Dickinson) after a final
PBS wash.
Transient transfection of hTfR1 and Western blot analysis
CHO-K1 cells were plated at 75% confluency in 10-cm
plates, 16 h. before transfection using Lipofectamine 2000
(Invitrogen, Carlsbad, CA, USA), according to the manufac-
turer's protocol. Briefly, a standard transfection mixture
containing 24 μg of a plasmid expressing hTfR1 and 60 μl of
Lipofectamine in serum-free media was added to each plate, the
cells were incubated for 4 h and cultured overnight in D10. The
following day, the cells were trypsinized and dispensed into 6-
well plates at 40% confluency. The next day, the cells were
transduced with vectors pseudotyped with test GPs, and titers
determined 48 h later, as described above.
A cell sample was collected at the time of transduction and
analyzed by Western blot to determine the levels of expression of
hTfR1. Cells were lysed in lysis buffer (20mMTris–HCl [pH7.5],
1%TritonX-100, 0.05%sodiumdodecyl sulfate [SDS] containing
5 mg/ml sodium deoxycholate, 150 mM NaCl and 1 mM
phenylmethylsulfonyl fluoride [Sigma]) at 4 °C for 10 min,
centrifuged in an Eppendorfmicrofuge at 16,000×g for 10min and
the cleared supernatants were diluted 1:1 in 2× SDS gel loading
buffer (Biorad, Hercules, CA) plus 5% 2-mercaptoethanol, boiled
for 10 min and electrophoresed in 8–16% polyacrylamide gels
(Biorad). The proteins were transferred to an Immobilon P poly-
vinylidifluoride fluoride transfer membrane (Millipore Corp.,
Bedford, MA) and blocked overnight at 4 °C with blocking buffer
(5%driedmilk in PBST [PBS {pH 7.4}, 0.1%Tween 20]). HTfR1
was detected using the mouse anti-human Tfr1 antibody clone
H68.4 (Invitrogen, Carlsbad, CA), diluted 1:500 in blocking
buffer, followed by horseradish–peroxidase-conjugated goat anti-
mouse IgG (1:10,000) (Pierce, Rockford, IL). Specific proteins
were visualized using the enhanced chemiluminescence detection
system (Amersham Biosciences Corp., Piscataway, NJ).
Anti-CD71 antibody pretreatment assay
293A or TRVb-1 cells were seeded in 12-well plates, 1 day
prior to transduction. Cells were pretreated with 5 nM or 50 nM
of mouse anti-human CD71 Ab (clone M-A712, BD Bios-
ciences, San Jose, CA), or medium alone, for 30 min in a 37 °C,
5% CO2 incubator. GP pseudotyped vectors were then added to
the mixture for an additional 4 h incubation. The antibody/
vector mixtures were then replaced with fresh D10 media and
the cells allowed to recover for 48–72 h before FACS analysis
to determine vector titers, as described above.
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